Thanks for the detailed answer, you provided great help CT. I understood the concept of how LL works, reminding me of learning from the animations and video explanations we had last spring. I admit it took a few viewings to wrap my pointy little head around it comfortably enough to feel good about investing, but I was unclear about how the competition's mABs worked in comparison. Of the two you explained, and from my layman's (at best) perspective, LL looks significantly superior in theory, adding to my anticipation of the CD12 results coming soon to a PR near you. Now I'm wondering about the other candidate in that article I hope I can find again, partnering with the US Army. The author favored this treatment as most promising among the three, while again failing to mention our favorite dark horse with the potential to win the race, leronlimab.